Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SAICoDis - Safety of Argatroban Infusion in Conduction Disturbances. A Prospective, Open, Multicenter Safety Study to Investigate Conduction Disturbances in Patients Receiving Argatroban Therapy.

NCT05740371 is registered in ClinicalTrials.gov with Tanabe Pharma GmbH as lead sponsor.

NCT NCT05740371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05740371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SAICoDis - Safety of Argatroban Infusion in Conduction Disturbances. A Prospective, Open, Multicenter Safety Study to Investigate Conduction Disturbances in Patients Receiving Argatroban Therapy.
Lead sponsor
Tanabe Pharma GmbH
Phase
Phase 4
Overall status
Completed
Start date
April 18, 2017
Completion date
May 6, 2021
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stable coronary artery disease (cad), unstable angina (troponin negative)